Coreg CR Gets Green Light for Generic Lifeline
Published Date: 5/30/2025
Notice
Summary
The FDA says COREG CR extended-release capsules (10, 20, 40, and 80 mg) weren’t pulled from shelves because of safety or effectiveness problems. This means generic versions can keep getting approved, so patients and pharmacies won’t face shortages or price spikes. If you use or make this medicine, things will keep running smoothly without any sudden changes.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generics remain available; no shortages
The FDA determined that COREG CR (carvedilol phosphate) extended‑release capsules — 10 mg, 20 mg, 40 mg, and 80 mg — were not withdrawn from sale for reasons of safety or effectiveness. That means the FDA will continue to allow approval of generic versions, so patients and pharmacies won’t face sudden shortages or price spikes for these strengths.
ANDA approvals will continue for COREG CR
The FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to COREG CR extended‑release capsules (10 mg, 20 mg, 40 mg, 80 mg) and will allow continued approval of ANDAs that meet legal and regulatory requirements. This preserves the pathway for generic manufacturers and applicants to obtain approvals for these products.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in